Jump to content

Search the Community

Showing results for tags 'lynparza'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • COMMUNITY
    • Announcements, meetings and other resources
  • ADVANCED PROSTATE CANCER FORUMS
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
  • MEMBER'S STORIES AND NEEDS
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Found 4 results

  1. Jim Marshall (not a doctor) said ... In this video Prostate Cancer Research Institute Executive Director Mark Scholz talks about a clinical trial for men who are metastatic and have rising psa on hormone therapy. The trial is testing whether adding the PARP inhibitor Lynparza (olaparib) to the super-hormone Zytiga (abiraterone) increases its effectiveness. You can find out about the clinical trial at: https://clinicaltrials.gov/ct2/show/study/NCT03732820?show_locs=Y#locn Details there include: inclusion details (things you need to get into the trial); exclusion details (what will keep you out of the trial); and locations. Australian locations include: Box Hill, Australia, 3128 Darlinghurst, Australia, 2010 Greenslopes, Australia, 4120 Herston, Australia, 4029 Kingswood, Australia, 2747 Kurralta Park, Australia, 5037 St Albans, Australia, 3021 Waratah, Australia, 2298 As always, ask your doctor if you think this might be for you. ... end Jim
  2. An interesting account by Professor Michael Hofman at the Advanced Prostate Cancer Consensus Conference in Basel, Switzerland recently. He speaks of the Lutetium-177 (Lu-177) treatment his team and others have done or are planning: https://www.urotoday.com/video-lectures/apccc-2019-conference/video/1467-players-brightcove-net2019-09-10-14-49-08.html Below the video is a full transcript - all the words Professor Hofman says in the video. Thanks to Nev and Lorraine
  3. I've previously posted on the forum here and here about Oliparib (brand name Lynparza) which is highly effective in treating men with DNA repair defects in their tumours, particularly those with mutations of the BRCA1 and BRCA2 genes. US oncologist, Dr Snuffy Myers, has now made a 10 minute video in which he talks about Oliparib.
  4. The United States Food and Drug Administration (FDA) has classified Olaparib (brand name Lynparza) as a Breakthrough Therapy for men with metastatic castrate-resistant prostate cancer with DNA repair defects in their tumours. This means the application to have Olaparib approved by the FDA for prostate cancer will be fast tracked and it is likely that Olaparib will be approved later this year. The FDA's decision to recognise Olaparib as a Breakthrough Therapy was reported in ONCLive
×
×
  • Create New...